Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Anteris Technologies Global Corp.
AVR
Latest revenue
$494.0K
as of 2026-03-31
Latest net income
$-23.0M
as of 2026-03-31
Net margin
-4660.7%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Orthopedic, Prosthetic & Surgical Appliances & Supplies (28 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AVR is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $937.4M
- Enterprise value
- $889.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 3.37×
- Dividend yield
- 0.0%
- 52-wk high
- $9.79
- 52-wk low
- $2.85
- Beta
- —
- Shares out
- 97.3M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Business Overview Anteris is a structural heart company dedicated to revolutionizing cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Our lead product, the DurAVR® THV System, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis — a potentially life-threatening condition resulting from a narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Our DurAVR® THV System consists of a…
AI summary unavailable — showing raw filing excerpt
Generated from AVR's filing dated 2026-02-26
Key risks
Risk Factors Risks Related to Our Business Risks Related to Our Operating History and Financial Position We have a history of operating losses and may not achieve or maintain profitability in the future. We have experienced recurring operating losses and negative cash flows from operating activities since inception. For the years ended December 31, 2025 and 2024, we had total losses after income tax of $94.2 million and $76.0 million, respectively, and negative cash flows from operating activities of $77.8 million and $61.2 million, respectively. As of December 31, 2025 and December 31, 2024, we had an accumulated deficit of $370.5 million and $276.4 million, respectively. We expect to…
AI summary unavailable — showing raw filing excerpt
Generated from AVR's filing dated 2026-02-26
Profitability
Operating margin
-4908.2%
69.3%Net margin
-4921.3%
74.4%Return on equity
101230.1%
83377.2%Return on assets
-409.4%
333.0%Leverage
Debt / equity
-248.28×
86967.4%Long-term debt / equity
-0.24×
Debt / assets
100.4%
351.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $494.0K | -11.2% | $-23.0M | -5.3% | -4660.7% |
Q4 2025 2025-12-31 | $310.0K | -42.2% | $-29.2M | -50.7% | -9420.0% |
Q3 2025 2025-09-30 | $429.0K | -44.2% | $-22.2M | -1.8% | -5185.1% |
Q2 2025 2025-06-30 | $618.0K | -2.2% | $-20.8M | -11.4% | -3371.2% |
Q1 2025 2025-03-31 | $556.0K | -27.4% | $-21.9M | -33.7% | -3932.4% |
Q4 2024 2024-12-31 | $536.0K | — | $-19.4M | — | -3614.9% |
Q3 2024 2024-09-30 | $769.0K | — | $-21.9M | — | -2842.4% |
Q2 2024 2024-06-30 | $632.0K | — | $-18.7M | — | -2960.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on AVR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$35.3M
Insider selling
$0
Net activity
+$35.3M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-01-22 | L1 Capital Pty Ltd 10%+ owner | Purchase | 5,000,000 | $5.75 | $28.8M | |
| 2025-10-28 | L1 Capital Pty Ltd 10%+ owner | Purchasederiv. | 1,333,334 | $4.93 | $6.6M |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AVR
Institutional value
$72.8M
Total shares held
13.1M
Distinct holders
55
-18 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4.9M | $27.1M | +2.9M (+141.2%) | Added |
| 2 | Ensign Peak Advisors, Inc | 2.1M | $11.6M | +686.6K (+49.0%) | Added |
| 3 | UBS Group AG | 1.4M | $7.8M | +891.1K (+172.8%) | Added |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 857.8K | $4.8M | — | New |
| 5 | Militia Capital Management LLC | 605.0K | $3.4M | — | New |
| 6 | Capricorn Fund Managers Ltd | 500.5K | $2.8M | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 476.3K | $2.6M | — | New |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 469.6K | $2.6M | — | New |
| 9 | SEVEN GRAND MANAGERS, LLC | 325.0K | $1.8M | — | New |
| 10 | Nuveen, LLC | 307.9K | $1.7M | +265.2K (+621.3%) | Added |
| 11 | Bank of New York Mellon Corp | 170.7K | $947.1K | +95.3K (+126.3%) | Added |
| 12 | Avidity Partners Management LP | 150.0K | $922.5K | — | New |
| 13 | BEARING POINT CAPITAL, LLC | 101.6K | $563.7K | +6.0K (+6.3%) | Added |
| 14 | Marex Group plc | 94.9K | $526.9K | — | New |
| 15 | Persistent Asset Partners Ltd | 85.9K | $476.8K | +62.6K (+268.5%) | Added |
| 16 | DEUTSCHE BANK AG\ | 71.9K | $399.2K | +43.1K (+149.2%) | Added |
| 17 | RHUMBLINE ADVISERS | 59.2K | $328.5K | +21.5K (+57.2%) | Added |
| 18 | WELLS FARGO & COMPANY/MN | 49.7K | $276.0K | +12.6K (+33.8%) | Added |
| 19 | Invesco Ltd. | 40.5K | $224.9K | +3.9K (+10.7%) | Added |
| 20 | JPMORGAN CHASE & CO | 32.4K | $165.6K | -1.4M (-97.7%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AVR's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.